SAN FRANCISCO - Friday, April 12th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Dolby Laboratories, Inc. (NYSE:DLB) will release financial results for the second quarter (Q2) of fiscal year 2013 after the close of regular trading on Thursday, April 25, 2013.

Members of Dolby management will lead a conference call open to all interested parties to discuss Dolby Laboratories’ Q2 fiscal 2013 financial results at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, April 25, 2013.

Access to the teleconference will be available over the Internet from http://investor.dolby.com/medialist.cfm or by dialing 1-888-296-4217. International callers can access the conference call at 1-719-325-2209.

A replay of the call will be available from 5:00 p.m. PT on Thursday, April 25, 2013, until 9:00 p.m. PT on May 2, 2013, by dialing 1-877-870-5176 (international callers can access the replay by dialing 1-858-384-5517) and entering the confirmation code 3736618. An archived version of the teleconf ... Read more »

RESEARCH TRIANGLE PARK, Caroline du Nord - Samedi 13 Avril 2013 [ME NewsWire]

(BUSINESS WIRE)--Quintiles a annoncé aujourd’hui avoir été choisi comme prestataire privilégié par Bristol-Myers Squibb Company (NYSE : BMY) afin de fournir au laboratoire pharmaceutique des services de support mondial aux travaux de laboratoires centraux ainsi qu'au développement de tests de biomarqueurs et de dosages pour les cinq années à venir.

« Cet accord renforce l’engagement que partagent nos entreprises qui est de donner accès aux patients à des traitements efficaces et sûrs à un prix abordable », a indiqué Thomas Wollman, vice-président senior de Quintiles Global Laboratories. « Nous nous réjouissons à l’idée de collaborer avec Bristol-Myers Squibb pour faire entrer la médecine personnalisée dans le courant dominant du développement de médicaments ».

À propos de Quintiles
... Read more »

Al-JUBAIL, Saudi Arabia - Saturday, April 13th 2013 [ME NewsWire]

( ... Read more »

New Financing Round Will Fund the Development of an Innovative Dry Eye Portfolio; First Product Targeted for Approval in 2013

HEIDELBERG, Germany - Saturday, April 13th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Novaliq GmbH, a drug delivery company with a focus on the efficacious topical application of poorly soluble drugs, today announced the successful completion of a fifth round of financing of €13.9m ($18.1m). Since 2007, the company has raised €27.1m ($35.2m).

Financing was again secured exclusively from the investment company of SAP, co-founder Dietmar Hopp’s Dievini Hopp Bio Tech Holding GmbH & Co. KG. With the new funds, the company intends to advance its lead projects into the medical device field to approval, progress its pharmaceutical project CyclASol™ into clinical development, and extend its technology platform.

Dievini is an active investor in life and health sciences companies focusing on innovative therapeutics and diagnostics faci ... Read more »

RESEARCH TRIANGLE PARK, N.C. - Friday, April 12th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Quintiles today announced that it has been chosen as a preferred provider by Bristol-Myers Squibb Company (NYSE:BMY) to provide global support for Bristol-Myers Squibb’s central lab work, biomarker testing and assay development for the next five years.

"This agreement deepens the commitment our companies share to providing patients access to effective, safe and affordable treatments,” said Thomas Wollman, Senior Vice President of Quintiles Global Laboratories. "We look forward to working with Bristol-Myers Squibb to bring personalized medicine into mainstream drug development.”

About Quintiles

Quintiles is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50, best-selling drug ... Read more »

Élargissement de la gamme de microcontrôleurs de contrôle moteur éconergétiques

TOKYO - Samedi 13 Avril 2013 [ME NewsWire]

(BUSINESS WIRE)--Toshiba Corporation (TOKYO : 6502) a annoncé qu'elle commencera à développer une nouvelle gamme de microcontrôleurs intégrés, comprenant notamment un coprocesseur de contrôle moteur avancé, le « Moteur vectoriel » (VE, Vector Engine).

La demande en matière d'énergie et de produits écoénergétiques augmente depuis quelques années. Toshiba travaille actuellement sur des solutions pour promouvoir une communauté intelligente dans divers domaines, et les semi-conducteurs constituent une part importante de cet effort. Les moteurs CA sont actuellement utilisés couramment dans les applications moteurs des secteurs consommation et industriel. Il existe néanmoins une forte demande sur le marché, notamment celui des produ ... Read more »

Expanding energy efficient product line of motor control microcontrollers

TOKYO - Friday, April 12th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today announced that it will start to develop a new product line of embedded microcontrollers including an advanced motor control co-processor, the "Vector Engine".

In recent years, demand has grown for energy and energy efficient products. Toshiba is working on solutions to promote smart community in various areas, and semiconductors form an important part of this effort. Currently, AC motors are commonly used in consumer and industrial motor applications but there is strong demand in the market, especially in consumer products, for more energy efficient DC motors. However, efficient control of DC motors requires high-level technical skills and a more simple solution is demanded.

Toshiba was one of the first companies to introduce co-processor-based vector control (vector engine) to impro ... Read more »